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Abstract: Pulmonary surfactant is a lipid/protein complex synthesized by the alveolar epithelium
and secreted into the airspaces, where it coats and protects the large respiratory air–liquid interface.
Surfactant, assembled as a complex network of membranous structures, integrates elements in charge
of reducing surface tension to a minimum along the breathing cycle, thus maintaining a large surface
open to gas exchange and also protecting the lung and the body from the entrance of a myriad of
potentially pathogenic entities. Different molecules in the surfactant establish a multivalent crosstalk
with the epithelium, the immune system and the lung microbiota, constituting a crucial platform to
sustain homeostasis, under health and disease. This review summarizes some of the most important
molecules and interactions within lung surfactant and how multiple lipid–protein and protein–protein
interactions contribute to the proper maintenance of an operative respiratory surface.
Keywords: pulmonary surfactant film; surfactant metabolism; surface tension; respiratory air–liquid
interface; inflammation; antimicrobial activity; apoptosis; efferocytosis; tissue repair
1. Introduction
In the lung, the essential function of respiration takes place through gas exchange between air and
blood. To allow this, a perfect architecture has been developed in which alveoli constitute the functional
units of the pulmonary system. There, a thin exchange surface structure is needed to ensure an effective
diffusion of oxygen to the capillaries, which is achieved by the existence of flattened alveolar epithelial
type I cells (AE1C) that constitute 95% of the total alveolar area [1]. On the other hand, the presence of
an air–water interface physically requires a reduction of the surface tension generated by the cohesive
forces between liquid molecules that, otherwise, would lead to shrinkage of alveoli [2]. To fulfill
this crucial role, alveolar epithelial type II cells (AE2C) secrete pulmonary surfactant, a lipid–protein
complex that forms a surface active film at the respiratory interface, allowing its stability and avoiding
alveolar collapse during expiration [3,4]. Moreover, beyond this main function, the huge respiratory
area exposed to external potentially harmful particles and microorganisms, entails an important
role of the lung in protection against pathogens, for which alveolar macrophages (AM) are critical,
together with the first line of defense constituted by surfactant [5].
Pulmonary surfactant is mainly composed of lipids (approximately 90% by mass), with phospholipids
constituting the principal class, with phosphatidylcholine (PC) as the predominant species (70–80%).
Among these, the saturated dipalmitoylphosphatidylcholine (DPPC) accounts for 40% in average
(although it can be as much as 50–55% of surfactant mass in humans, pigs, rats or mice), whereas unsaturated
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PC and anionic phospholipids as phosphatidylglycerol (PG, 8%) and phosphatidylinositol (PI) are
also important components. Surfactant also contains neutral lipids as cholesterol, which represents
approximately 5–8% in weight. Other less abundant phospholipids include phosphatidylethanolamine,
phosphatidylserine and sphyngomyelin, as well as traces of triglycerides and fatty acids [2,6]. Besides lipids,
surfactant contains proteins (approximately 10%) from which those surfactant-specific proteins (6–8%)
play essential roles to sustain the proper structure and function of the system. SP-B and SP-C are small
highly hydrophobic and cationic proteins required to perform optimal surfactant biophysical properties,
that is, formation and stabilization of the interfacial film during respiratory dynamics [7–10]. On the other
hand, hydrophilic proteins SP-A and SP-D belong to the collectin (C-type collagen-containing lectins)
family, characterized by its ability to recognize and bind to pathogens, providing these proteins with a
lung-defense related role [11].
Surfactant lipids and proteins are synthesized in AE2C and assembled into highly packed
membranous organelles called lamellar bodies (LB), which are then secreted to the thin fluid phase that
lines alveolar spaces [12,13]. Surfactant membranes quickly adsorb to the air–liquid interface to form
the functional film that is able to achieve minimal surface tension values upon the reduction of surface
area that occurs at expiration, as well as allowing an effective respreading of material during alveolar
expansion at inspiration [2]. The finely tuned composition and structure of surfactant complexes
are responsible for providing its stabilizing and dynamic properties, so that the presence of certain
lipids and proteins (mainly SP-B and SP-C), as well as the formation of a surface-associated multilayer
reservoir, are essential for the optimal function of surfactant. Once material is somehow spent and
detaches from the interfacial film, recycling (by AE2C) or degradation (by AE2C and AM) take place by
regulated routes, ensuring an appropriate amount of operative surfactant at the alveolar spaces [14].
Maintaining lung homeostasis is crucial, including a tight regulation of many different processes
occurring at the alveolar and perialveolar environments. Perturbation of any of these regulatory
mechanisms entails lung injury and several pulmonary pathologies [13]. First, a balance must
be accomplished between inflammatory responses necessary to defend the lung against toxins or
pathogens and the need of a basal toleration to avoid exacerbated reactions [15]. Besides this immune
homeostasis, ensuring the availability of a proper amount of surfactant with accurate composition
and structure, under several physiological or pathological situations, is essential for stabilizing the
respiratory surface and supporting alveolar homeostasis [16]. In this review we describe the central
role of pulmonary surfactant in different aspects of lung homeostasis, highlighting the importance of
lipid–protein and protein–protein interactions in achieving this vital function.
2. The Essential Role of Pulmonary Surfactant at the Lung Interface
2.1. Formation, Stability and Dynamics of the Surfactant Film: Protein and Lipid Interaction
Upon secretion of lamellar bodies from AE2C into the alveolar liquid subphase, surfactant unpacks
and quickly adsorbs to the air–liquid interface forming the surface-active film (Figure 1). This essential
ability, together with the reduction of surface tension to very low values during compression of
the alveolus and the efficient re-extension of material during inspiration, are strictly required for
an effective biophysical function of surfactant, and rely on its particular lipid–protein composition.
The saturated acyl chains of the main surfactant phospholipid DPPC are essential to allow for maximal
packing of the interfacial film upon reduction of surface area at expiration, thus, reducing surface
tension to extremely low values. However, DPPC is not able to efficiently adsorb to the air-water
interface by its own, so that anionic and unsaturated phospholipids, together with surfactant proteins,
play an essential role in this process [17]. These surfactant components are also required for the
generation of a multilayer reservoir of material that is formed during compression of the surface film,
once the most fluid regions of the film are forced to fold, leading as a consequence to an enrichment
of the air-exposed monolayer in highly packed DPPC-enriched domains (Figure 2). This reservoir of
associated membranes, which remains attached to the interfacial film and also incorporates newly
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arriving surfactant complexes, provides stability and allows fast re-extension of material into the
increasing surface area during inspiration [18,19].
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[19]. Extracellular surfactant structures include a membrane network promoted by SP-A and SP-B 
(tubular myelin) [24] and membrane arrangements of different complexity [25]. After exposure to 
air, surfactant “used” membranes are converted into small vesicles [26] in a SP-D-mediated process 
[27] that can be at least partly re-uptaken by AE2C, a process promoted by SP-A [28]. SP-A also acts
as a secretion inhibitory signal [29], in an opposing role to that of SP-B as secretion inducer [30].
Components captured by AE2C are routed to the recycling pathway or degraded [14]. Besides,
alveolar macrophages account for a 20% of surfactant clearance [31], for which the presence of
granulocyte-macrophage colony stimulating factor (GM-CSF) is required [32]. Alveolar homeostasis
highly depends on the effective cross-talk between alveolar macrophages (AM) and AE2C and the
maintenance of lipid homeostasis in both cells, involving a proper reverse cholesterol transport (RCT) 
mediated by ABCA1 and ABCG1 lipid transporters [33–35]. SP-A is represented as its most abundant 
octadecameric form; SP-B as double rings, each formed by six dimers; SP-C as monomers; SP-D as
dodecamers.
Figure 1. Protein/protein and protein/lipid interactions are essential for maintaining surfactant
homeostasis at the alveolar spaces. Surfactant components are synthesized by AE2C and assembled
in lamellar bodies (LB). Proper formation of these highly packed lipid organelles requires the
presence of SP-B and ABCA3 [20,21]. Upon secretion to the alveolar fluid, surfactant is efficiently
adsorbed into the air–liquid interface, in a process highly dependent on the presence of proteins SP-B
and SP-C [22,23]. Multilayered membranous surfactant structures associate to the interfacial film
forming a reservoir, which provides mechanical stability and a source of material upon respiratory
dynamics [19]. Extracellular surfactant structures include a membrane network promoted by SP-A and
SP-B (tubular myelin) [24] and membrane arrangements of different complexity [25]. After exposure to air,
surfactant “used” membranes are converted into small vesicles [26] in a SP-D-mediated process [27] that
can be at least partly re-uptaken by AE2C, a process promoted by SP-A [28]. SP-A also acts as a secretion
inhibitory signal [29], in an opposing role to that of SP-B as secretion in ucer [30]. Components captured
by AE2C are routed to the recycling pathway or degraded [14]. Besides, alveolar macr phages account for
a 20% of surf c ant clearance [31], for which the pr sence of granulocyte-macrophag colony stimulating
facto (GM-CSF) is required [32]. Alveolar homeostasis highly dep nds on the effective cross-talk b tween
alve lar macrophages (AM) and AE2C and the maintenance of lipid homeostasis in b th cells, involving a
proper reverse cholesterol transport (RCT) mediated by ABCA1 and ABCG1 lipid transporters [33–35].
SP-A is represented as its most abundant octadecameric form; SP-B as double rings, each formed by six
dimers; SP-C as monomers; SP-D as dodecamers.
Int. J. Mol. Sci. 2020, 21, 3708 4 of 39
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 40 
 
 
Figure 2. Lipid–protein interactions in the mechanical stabilization of alveoli during breathing cycles. 
Surfactant proteins SP-B and SP-C facilitate surfactant dynamics by regulating the mechanical 
properties of surfactant membranes and films through direct interaction with fluid-like lipids [36], 
including PG. Binding of SP-B and SP-C to unsaturated and anionic lipids would produce protein 
partitioning into fluid domains that may contribute to highly curved membranes [37], promoting 
lipid polymorphism [38–42] and favoring a compression-driven enrichment of the interfacial film in 
the most surface active component of surfactant, DPPC. On the other hand, by binding to DPPC at 
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simultaneously to different membranes through its carbohydrate recognition domains [10]; SP-B 
forms rings (shown as hexamers of dimers) and tubes that connect different bilayers [45,46], and SP-
C maintains insertion of palmitoylated cysteins at its N-terminal segment into highly packed liquid-
ordered regions of the interfacial film [47,48]. Surfactant membranes may be further stabilized during 
the breathing cycles by SP-A/SP-B and SP-B/SP-C interactions. Notice that surfactant proteins in the 
cartoon are not represented at equivalent scale. 
Hydrophobic proteins SP-B and SP-C are required for efficient surfactant unpacking upon 
secretion, and for the formation of the surface film [22]. SP-B in particular plays a vital function in 
surfactant biophysics. This protein, which belongs to the saposin family, shows lipid membrane 
fusion and lysis activities that have been ascribed to the different segments of the sequence [49–51]. 
The lipid–protein and protein–protein interactions behind these SP-B properties are responsible for 
its role in promoting efficient surfactant adsorption and re-extension as well as in maintaining film 
stability at low surface tensions [17,23]. SP-B is known to be able to generate contacts among 
membranes [52], and we have shown that SP-B is able to oligomerize into ring structures formed by 
association of dimers, with a hydrophobic cavity inside [53]. Docking of SP-B oligomers would allow 
the connection of contiguous surfactant structures and the generation of a hydrophobic tunnel 
through which lipids could rapidly be transferred across the alveolar fluid phase, adsorbing towards 
the interfacial film [45,46]. The cohesivity among surfactant membranes provided by SP-B protein–
protein interactions would also be important for supporting film stability [54]. Besides offering a 
hydrophobic pocket, the orientation of the amphipatic α-helices of SP-B at the surface of surfactant 
layers allows electrostatic interaction of positively-charged residues at the protein with the polar 
heads of surfactant anionic phospholipids, mainly PG. Within the literature, there is some evidence  
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Figure 2. Lipid–protein interactions in the mechanical stabilization of alveoli during breathing
cycles. Surfactant proteins SP-B and SP-C facilitate surfactant dynamics by regulating the mechanical
properties of surfactant membranes and films through direct interaction with fluid-like lipids [36],
including PG. Binding of SP-B and SP-C to unsaturated and anionic lipids would produce protein
partitioning into fluid domains that may contribute to highly curved membranes [37], promoting lipid
olymorphism [38–42] and favoring a compression-driven enrichment of the i terfacial film in the
most surface active compone t of surfactant, DPPC. On th other and, by binding to DPPC at
solid/fluid phase in erfa es, SP-A pr motes demixing of surfactan lipids, facilitat g the segregation
of unsaturated phospholipids at the interfac [43] and, thus, modeling the mecha ical prop rties of
the surfactant film [44]. In addition, surfactant proteins A, B and C stabilize multilayered interfacial
structures a d preclude the out- f-plane relaxati n of the surfactant film at the end of xpiration by
promoting membrane-membrane contacts: SP-A ( ligomer shown, octadec mer) binds simult neously
to different membranes through its carb hydrate recognition d ains [10]; SP-B forms rings (show as
hexamers of dimers) and tubes that connect different bilayers [45,46], and SP-C maintains insertion
of palmitoylated cysteins at its N-ter inal segment into highly packed liquid-ordered regions of the
interfacial film [47,48]. Surfactant membranes may be further stabilized during the breathing cycles by
SP-A/SP-B and SP-B/SP-C interactions. Notice that surfactant proteins in the cartoon are not represented
at equivalent scale.
Hydrophobic proteins SP-B and SP-C are required for efficient surfactant unpacking upon secretion,
and for the formation of the surface film [22]. SP-B in particular plays a vital function in surfactant
biophysics. This protein, which belongs to the saposin family, shows lipid membrane fusion and lysis
activities that have been ascribed to the different segments of the sequence [49–51]. The lipid–protein
and protein–protein interactions behind these SP-B properties are responsible for its role in promoting
efficient surfactant adsorption and re-extension as well as in maintaining film stability at low surface
tensions [17,23]. SP-B is known to be able to generate contacts among membranes [52], and we have
shown that SP-B is able to oligomerize into ring structures formed by association of dimers, with a
hydrophobic cavity inside [53]. Docking of SP-B oligomers would allow the connection of contiguous
surfactant structures and the generation of a hydrophobic tunnel through which lipids could rapidly be
transferred across the alveolar fluid phase, adsorbing towards the interfacial film [45,46]. The cohesivity
among surfactant membranes provided by SP-B protein–protein interactions would also be important for
supporting film stability [54]. Besides offering a hydrophobic pocket, the orientation of the amphipatic
α-helices of SP-B at the surface of surfactant layers allows electrostatic interaction of positively-charged
residues at the protein with the polar heads of surfactant anionic phospholipids, mainly PG. Within the
literature, there is some evidence suggesting a preferential interaction of SP-B and SP-C with anionic
phospholipids [45,55–57]. This PG/SP-B interaction could be important for the orientation of the
protein in the membrane. As a matter of fact, the effect of PG to facilitate surfactant adsorption and
in maintaining the stability of the film, was early related to its interaction with cationic hydrophobic
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proteins, and in particular, with SP-B [58]. The possibility that SP-B oligomer could form a proteolipidic
pore implies also the involvement of phospholipids, especially PG, as essential determinants of lipid
transfer/adsorption properties of surfactant [45,53,59]. Apart from PG, unsaturated phospholipids play
also a role in favoring surfactant adsorption, facilitating a dynamic insertion of the material into the
interfacial film [60]. On the other hand, molecular dynamics simulations have very recently proposed
potential selective interactions of SP-B with cholesterol, an interesting possibility whose functional
implications have still to be clarified [45]. Protein/protein and lipid/protein interactions involved in the
formation, stability and dynamics of the surfactant film are summarized in Table 1.
Regarding SP-C, beyond its implication in promoting surfactant adsorption [22,61], it has been
ascribed a role in maintaining attachment of the surfactant reservoir to the interfacial monolayer,
thus providing stability [62–65]. A potential cooperation between SP-B and SP-C in biophysical functions
in surfactant could be inferred from several studies, including their synergic action in permeability and
lipid transfer properties of surfactant [22,23,59,66]. As a matter of fact, a surfactant containing both
proteins, SP-B and SP-C, exhibits superior functional properties to facilitate breathing, as tested in vivo,
than surfactant preparations lacking one of the hydrophobic proteins [64,67]. Thus, the existence of
direct interactions between both proteins has been considered as an interesting possibility, which finally
was recently demonstrated by advanced fluorescence spectroscopy techniques [68]. A model has been
proposed in which SP-C could also regulate the interaction between SP-B oligomers. The specific
and opposing roles of both hydrophobic proteins is revealed by the destabilizing effect of SP-C upon
lipid vesicles versus the fusogenic activity of SP-B, and might have functional implications along the
surfactant cycle [66,69]. Concerning the preferential interactions of SP-C with lipids, besides PG the
protein has been proposed to specifically interact with cholesterol [70]. This neutral lipid is important
for maintaining a proper fluidity and viscosity in surfactant, thus facilitating the dynamical properties
of the membranes [71–73]. However, cholesterol proportion in surfactant must be tightly controlled,
so that its increase has been related to functional inhibition [74–76]. The presence of SP-C seems to be
critical to ensure the proper function of surfactant in the presence of cholesterol [47,77,78], and the
combined action of SP-B and SP-C could be important for the removal of cholesterol during film
refining at expiration [69].
Despite hydrophobic proteins are the principal players in the biophysical activities of surfactant,
the hydrophilic SP-A is also important for an optimal function. This protein, which forms oligomers
consisting of six trimers, is able to bind DPPC and cholesterol through its carbohydrate recognition
domain (CRD) [79]. SP-A induces calcium-dependent vesicle aggregation and enhanced surface
adsorption [80,81], requiring for it a supratrimeric assembly [82]. The interaction of the protein with
cholesterol could be involved in the protecting role of SP-A against the surfactant dysfunction produced
as a consequence of supraphysiological concentrations of this neutral lipid [83]. Interestingly, slightly
different biophysical activity has been found in the two proteins encoded by the two SP-A-related
human genes, SP-A1 and SP-A2, which differ in several features of its structure [84,85]. In particular,
SP-A1 has been shown to be important for the efficient adsorption of surfactant phospholipids and for
the reorganization of the surface film during breathing-like compression-expansion cycles. This role
could be related to the high level of oligomerization of SP-A1, which could assist in the formation
of the highly cohesive multilayer film, for which SP-B is essential [43]. The existence of recently
found protein–protein interactions between SP-A and SP-B [86] would also support the concerted
action of both proteins in surfactant processes, and some evidences even suggest the possibility of
different modes of interaction of SP-A1 and SP-A2 with SP-B [87], although precise information is still
lacking. Thus, protein–protein cooperation could be crucial for developing SP-A physiological roles in
surfactant at different levels, including enhancing surfactant adsorption, optimizing film stability and
allowing the formation of specific surfactant structures at the alveolar spaces, as tubular myelin [10].
Finally, SP-D, which is not involved in the biophysical activity of surfactant, is not lipid-associated
although preferential binding to PI has been proposed, with potential implications for the regulation of
surfactant homeostasis, as will be discussed later [88].
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Table 1. Summary of protein/protein and protein/lipid interactions involved in alveolar homeostasis
through regulation of surfactant film formation and stability, as well as surfactant levels in
alveolar spaces.
Surfactant Protein Interacting Protein or Lipid Functional Role References
SP-A
SP-B
Interfacial adsorption
Secretion regulation *
Cohesivity of multilayer reservoir *
[43,80,81,86]
[30]
[80]
SP-B/PG Interfacial adsorptionTubular myelin formation
[89]
[24]
DPPC Lipid re-uptake to AE2C [90]
Cholesterol Protection against inhibition [83]
PLA2 Lipid degradation inhibition [91]
SP-B
SP-B
Interfacial adsorption (lipid transfer)
Permeability
Cohesivity (membrane stacking)
LB assembly (membrane stacking)
[22,45,46,53]
[59,66]
[46,52]
[52]
SP-C
Interfacial adsorption
Modulation of permeability and lipid
transfer
Pro SP-C processing *
[22,23]
[59,66,68]
[68]
PG Interfacial adsorption and film stability [45,58,59,92]
Cholesterol * Unknown [45]
SP-C
PG Interfacial adsorption [58]
Cholesterol
Cholesterol removal from interfacial
film (refining)
Cholesterol removal from alveolar
spaces *
Crosstalk AE2C-AM
[47,69,77]
[69]
[78]
SP-D
PI Regulation of re-uptake to AE2C [27,93,94]
GPR116 * Regulation of secretion and re-uptake * [95]
* Suggested potential interactions or roles.
2.2. Alteration of the Interfacial Surfactant Film is Cause of Lung Injury
As previously described, the surfactant film is essential for reducing surface tension avoiding
collapse of alveoli. The presence of surfactant itself is therefore the first indispensable requirement
for maintaining lung homeostasis, stabilizing alveoli and preventing edema formation. Besides this,
surfactant precludes interfacial stress forces that could deform and cause dysfunction of AE2C as a
consequence of their contact with the air–liquid interface [96,97]. This role of surfactant in alveolar
micromechanics entails that its deficiency or dysfunction, either by primary (e.g., absence of SP-B,
AE2C injury) or secondary (as lung inflammation) causes, triggers lung injury [98,99].
Surfactant deficiency or alteration has been associated with the leading causes of acute respiratory
distress syndrome (ARDS), which refers to inflammatory processes frequently associated with lung
injury. Inflammation itself mediates AE2C injury, but also liberation of pro-inflammatory mediators
and cell and tissue debris, all contributing to an altered composition of surfactant. A complex
group of alterations are found in alveolar spaces at ARDS: reduced amount of surfactant lipids and
proteins, altered profiles of surfactant protein intermediates and byproducts, increased levels of plasma
proteins (because of the increased capillary permeability) that produce surfactant inhibition, increased
surfactant hydrolysis of surfactant by secretory phospholipase A2 (PLA2) and release of reactive
oxygen species [100–104]. Absence of SP-C and decreased levels of SP-A and SP-B are associated with
familial interstitial lung disease [105]. Decreased levels of SP-A and/or SP-D are also observed in
neonates with respiratory distress syndrome (RDS) and patients with idiopathic pulmonary fibrosis,
bacterial pneumonia, chronic obstructive pulmonary disease, and asthma (reviewed in [106–108]).
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Reduced amounts of lung collectins in the lung increase the susceptibility to respiratory infections,
promote inflammation and hamper the elimination of apoptotic cells leading to abnormal lung tissue
regeneration as described in the following sections. The finding that elderly people show reduced
levels of SP-A in the lungs [109,110] suggests that ageing may aggravate the clinical consequences of
surfactant deficiency, particularly in chronic obstructive pulmonary disease and idiopathic pulmonary
fibrosis [111]. On the other hand, since lung collectins levels are usually reduced in the lung because
of protein leakage towards the vascular compartment, serum levels of these proteins are considered
biomarkers of disease severity and predictive factors of unfavorable disease outcome [112–115].
Genetic deficiency of SP-B is rare, and occurs as a consequence of mutations leading to the
absence of SP-B or proSP-B proteins. The disease is characterized by the lack of properly packed
lamellar bodies, absence of mature SP-C and appearance of unprocessed proSP-C forms [102,116–118].
Unless partial deficiency in SP-B production still allows a certain production of SP-B [119,120],
this genetic deficiency gives rise to a lethal RDS upon birth, requiring early lung transplantation to
survive [121]. Gene therapy would be thus an essential tool to reverse the usually lethal SP-B deficiency,
and promising progress has been recently made in the production of human lung organoids [122].
In the case of adults carrying mutations in heterocygosis, susceptibility to lung diseases in the
adulthood has been described, particularly among smokers [123]. Unlike SP-B, genetic SP-C deficiency
is not usually a cause of neonatal RDS, but interstitial lung disease, including pulmonary fibrosis,
can appear at long-term [124–126]. Pathophysiology of the disease caused by SP-C mutations is
mainly related to AE2C cell damage, produced by endoplasmic reticulum (ER) stress due to proSP-C
misfolding, or to its altered traffic to lamellar bodies [102]. On the other hand, different studies have
shown that mutations in the genes encoding SP-A1 and SP-A2 are also involved in lung diseases.
For example, mutations that affect the CRD domain of SP-A1 (W211R) or SP-A2 (G231V and F198S) are
associated with idiopathic interstitial pneumonia [127] and pulmonary fibrosis [128,129], respectively.
These mutations impair protein secretion and promote protein aggregation within the ER, increasing ER
stress at resident AE2C [129]. In addition, genetic polymorphisms of lung collectins are known to be
associated with susceptibility to acute lung injury [130], RDS [131] and infections [132,133]. In the
case of acute lung injury, a polymorphism that causes the insertion or deletion of three amino acids
within the collagen-like domain of SP-A1 has been related to the reduced water levels in the lung
characteristic of this disease, probably due to alterations in the structure and binding properties of
the protein [130]. Complex interactions of single nucleotide polymorphisms of the genes that encode
all surfactant proteins seem to contribute to the pulmonary disease in cystic fibrosis patients [134].
Similarly, interactions between SP-A1 and SP-B polymorphisms are involved in genetic susceptibility
to RDS [135].
3. Surfactant Homeostasis in the Alveolar Spaces
To ensure the presence of a functional surfactant film at the respiratory interface, synthesis,
secretion, reuptake and degradation of surfactant components must be perfectly regulated and
balanced. This includes achieving both a precise composition of lipids and proteins and their proper
organization in defined surfactant structures at the alveolar spaces, together with an efficient cross-talk
established between epithelial cells and alveolar macrophages. Protein and lipid interactions involved
in surfactant homeostasis are also summarized in Table 1.
3.1. Synthesis, Storage and Secretion of Pulmonary Surfactant
De novo synthesis of surfactant phospholipids takes place at the endoplasmic reticulum in AE2C.
PC is synthesized from choline by the Kennedy pathway, which includes several enzymatic steps,
with the cytidine triphosphate-phosphocoline cytidyltransferase (CCT) controlling the synthesis rate.
A parallel formation of diacylglycerols occurs coupled to this pathway (for a recent review on surfactant
metabolism see [13]). Direct interaction of acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT1)
with the STAR10 (steroidogenic acute regulatory-related lipid transfer protein 10) protein has been
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found to be important for trafficking of newly synthesized DPPC from endoplasmic reticulum to
LB [136], which seems to occur by direct non vesicular transport between both organelles, apparently
skipping Golgi and multivesicular bodies [137]. In fetal mouse lung, glycogen storages present in
AE2C, in which CCT is also found, seem to provide substrate for PC biosynthesis [138,139]. Besides this,
triglycerides have been also shown to be directed from alveolar lipofibroblasts to AE2C and contribute
to the fetal surfactant phospholipid pool, pointing to a cross-talk between these two cell types to
ensure surfactant homeostasis [140,141]. Apart from this de novo synthesis, in the Lands cycle DPPC
is also obtained by remodeling from unsaturated PC by PLA2 and LPCAT1, being the latter also
involved in the synthesis of PG. These two enzymes, together with CCT, have been shown to be key
players for the proper regulation of surfactant synthesis, so that their alteration is cause of respiratory
distress [142–144]. In the case of LPCAT1, it has been ascribed a role in coordinating the two pathways
of DPPC synthesis according to the physiological demands of surfactant at the alveolar spaces [145].
Besides this, the finding that peroxiredoxin 6, a multifunctional enzyme with PLA2 and LPCAT
activities, is located in lamellar bodies, pointed to these organelles as a sufficient location for DPPC
remodeling [146]. Regarding to PLA2, not only this enzyme has a key role in regulating the turnover
of surfactant phospholipids because of its implication in their synthesis and degradation, but it is also
involved in antioxidant and cell signaling roles [147]. Finally, the interaction of SP-A with peroxiredoxin
leads to inhibition of its PLA2 activity, pointing to a potential role of SP-A in regulating surfactant
phospholipids turnover [91,148]. With regard to cholesterol, apart from the principal plasmatic source,
it can be also synthesized in peroxisomes in AE2C, whereas cholesterol-binding proteins have been
found in lamellar bodies, suggesting a potential implication of the Niemann–Pick C pathway in the
regulation of surfactant cholesterol and homeostasis [149,150]. Finally, alveolar lipofibroblasts could
also participate in cholesterol supply to surfactant under certain conditions [141].
The synthesis and complex processing of proteins SP-B and SP-C initiate in the endoplasmic
reticulum of AE2C, and occur coupled to surfactant lipid synthesis and intracellular trafficking.
Both proteins are produced as large soluble precursors where the mature hydrophobic modules are
protected by flanking N- and C-terminal domains [13]. Processing of precursors takes place in transit
to LBs via multivesicular bodies, and consists of several proteolytic cleavages and post-translational
modifications, in a route coupled to sequential acidification. Thus, maturation of both proteins is
conducted in a concerted way, being SP-B required for proper SP-C processing [117] by mechanisms that
are still unknown, although they could well involve the previously described SP-B/SP-C interactions [68],
or even potential interactions between its precursors. Furthermore, the fusogenic and lytic properties
behind membrane remodeling abilities of SP-B, together with its role in generating membrane
contacts, turn SP-B into an essential requirement for the formation of correctly assembled LBs [20,151].
These organelles are formed by packed lipid membranes in a well-defined structure that, in the case of
humans, is arranged as concentric lamellae [152]. Surfactant lipids, at least PC, PG and cholesterol,
are imported and accumulated into LBs by their limiting membrane transporter ATP binding cassette
subfamily A member 3 (ABCA3), in an ATP-depending process [21,153,154]. The coupling between
lipid and protein synthesis, processing and assembly in LBs places all these actors as essential providers
of surfactant homeostasis, so that their disruption leads to alteration affecting the rest of components
of the system and inadequate surfactant production. Thus, absence of CCT is cause of changes in
surfactant protein levels and aberrant LBs [142], mutations in ABCA3, or in its interacting protein
EMC3 (endoplasmic reticulum membrane protein complex subunit 3), which is required for ABCA3
stabilization, produce absence of lamellar bodies and misprocessed surfactant proteins [155,156],
and decrease of SP-B levels affects SP-C processing and LB formation, as previously stated. On the
other hand, mutations in the SP-C gene, as previously described, are related to long-term lung diseases,
including fibrosis, and injury to AE2C by endoplasmic reticulum stress due to protein misfolding
(mutations affecting SP-C precursor) [102]. Finally, absence of ABCA3 has been also related to AE2C
apoptosis by endoplasmic reticulum stress due to the accumulation of phospholipids and cholesterol,
which are then rerouted to the endoplasmic reticulum from LB [154].
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Hydrophilic proteins SP-A and SP-D are synthesized in the endoplasmic reticulum,
where post-translational modifications and oligomerization also occurs. The main route of secretion
of these proteins is via constitutive non-regulated vesicular transport, bypassing LBs, although a certain
proportion of synthesized SP-A seems to be directed to these organelles, together with the recycled protein
recovered from alveolar spaces [13]. Due to the role of hydrophilic proteins in lung immunomodulation,
their absence produces increased inflammation [157], although alterations in surfactant homeostasis are
also found, related to their involvement in surfactant catabolism [90,158], as it will be discussed later.
LBs are secreted to the alveolar fluid in response mainly to alveolar stretching produced during
inspiration, through stimulation by purinergic agonists such as ATP. The stimulation of AE2C by
ATP leads to an increase in cytoplasmic calcium, both by entry from the alveolar medium and
by release from intracellular stores, mainly endoplasmic reticulum. Calcium triggers LB secretion
by regulating the direct fusion of LBs with the plasma membrane and by cytoskeleton activation.
Generation of the fusion pore, involving soluble SNARE (N-ethylmaleimide-sensitive factor attachment
receptor) proteins at both the LB and the cell membrane, triggers a local entry of extracellular calcium
(fusion-activated calcium entry) that expands the pore and allows surfactant release, which requires
compression of the vesicle by an actin coat [13]. Regulation of surfactant secretion is essential to
maintain alveolar homeostasis. Extracellular SP-A was described as an inhibitor of secretion by
interaction with its receptor tumor protein 63 (P63) at the AE2C membrane [28,29], although little is
known about the mechanisms involved in sensing the availability of surfactant at the alveolar spaces
and the possible need for secretion of material. Stretching sensing has been traditionally ascribed to
AE1C, which would as a result induce LB secretion through the increase of extracellular ATP [159].
However, an implication of the air–liquid interface itself has been reported, so that AE2C could be
able to sense the mechanical forces produced by the thinning of the aqueous phase and the increase
in surface tension, responding with intracellular calcium increase, thus promoting the secretion of a
surplus of new surfactant material. Besides this, AE2C could be also capable of activating cellular
responses involved in cell repair, to prevent lung injury [96,97]. On the other hand, extracellular SP-B
has been recently found to stimulate surfactant secretion by the purinergic pathway, so that the protein
could ensure the availability of enough density of surfactant and a proper membrane network at the
alveolar spaces, and thus, surfactant homeostasis [30]. The molecular mechanism of this regulation
needs still to be investigated, as well as the potential existence of a “SP-B receptor” at the AE2C plasma
membrane. The possibility that SP-B/SP-A interactions [86], as a secretion activator/inhibitor couple,
might be involved in a concerted regulation of surfactant secretion will require further investigation.
Finally, a potential role as sensor of the surfactant pool size or its composition has been postulated
for G-protein coupled receptor 116 (GPR116), a transmembrane receptor of AE2C that has been
identified as a negative regulator of surfactant secretion. The sensing mechanism of this protein
could rely on its interaction with some surfactant component(s) which, up to now, has not been yet
identified [160,161]. However, suggested possibilities for GPR116 sensing include interaction with
SP-D or its direct modulation by mechanical stretching upon inspiration [162].
3.2. Surfactant Structures in the Alveolar Spaces
Once surfactant is secreted into the alveolar fluid, fast adsorption of material takes place and new
components are transferred into the air–liquid film. The specific mechanisms converting the secreted
highly packed membrane structures into part of the interfacial film are not still completely understood.
SP-B/SP-C common machineries have been shown to be essential for unpacking of secreted surfactant
LB-like particles and formation of the surface film, pointing to the possibility that, upon contact with
the air-water interface, SP-B nanorings, regulated by SP-C, would trigger the fast transfer of lipids into
the film [22]. Apart from these freshly secreted structures, another surfactant assembly that could act
as an intermediate between LB and the interfacial film, is tubular myelin (Figure 1). Tubular myelin is
a complex three-dimensional membranous tubular structure, whose formation requires the presence of
SP-A (in humans, both SP-A1 and SP-A2), SP-B, and anionic lipids, highlighting once again the essential
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role of the interactions among these surfactant components [24,163,164]. Although the particular
function played by tubular myelin is still unknown, as its presence is not essential for respiration [165],
potential roles could be related with the involvement of SP-A in antimicrobial defense.
The study of the extracellular surfactant recovered from alveolar spaces led to the finding that
two different pools of surfactant are present, in terms of size, composition and structural complexity.
The more dense surfactant material known as large aggregates (LA), which contains secreted LBs,
tubular myelin and SP-A, SP-B and SP-C, is thought to be somehow metabolically converted into
another form rich in small vesicles (small aggregates or SA) with decreased content in proteins and
a lower adsorption activity [25,26]. Of note, an increased SA/LA ratio is found in patients suffering
ARDS [103]. The conversion of LA to SA can be reproduced in vitro by compression-expansion cycling
of the interfacial film, so that it is generally assumed that the smaller structures are generated by
the “used” surfactant components once surfactant has been exposed to a dynamic air-water interface
(Figure 1). The physiological role of these structural changes of surfactant seems to be encompassed in
an important mechanism of surfactant homeostasis regulation, as it will be discussed below.
3.3. Surfactant Recycling and Catabolism
The proper regulation of surfactant pool size includes the clearance of the used surfactant
from the alveolar spaces, thus avoiding the excessive accumulation of a spent, substantially altered
(including extensive oxidation) material that can lead to lung injury and inflammation. Surfactant is
removed from the alveolar fluid by re-uptake to AE2C for recycling or degradation, and to alveolar
macrophages for its catabolism. Surfactant pool size itself has been shown to induce the increase of
catabolic rate, thus maintaining alveolar homeostasis, although the molecular pathways involved in
such response are not clear [166].
Apart from inhibiting surfactant secretion, SP-A contributes to alveolar homeostasis by stimulating
the phospholipid uptake by AE2C via clathrin-mediated endocytosis upon interaction with its receptor
P63 [28]. A similar case is GPR116, which acts both as secretion inhibitor and as stimulator of
pneumocyte re-uptake, for which potential interactions with SP-D may be involved [95,162]. As a
matter of fact, SP-D seems to play an essential role in the regulation of surfactant pool size. This protein
is involved in the structural remodeling of surfactant structure into SA, which is the form taken
up by AE2C to proceed with surfactant recycling or degradation (Figure 1). To achieve this role,
for which SP-D oligomeric structure is required [167], the protein seems to induce fragmentation
of surfactant membranes, for which its interaction with PI has been suggested to be a determinant
factor [27,94,168]. On the other hand, the structure of surfactant aggregates does not influence its
uptake by AMs [169], and although SP-D is able to bind to the surface of these cells to modulate
inflammation, the homeostasis/immune roles of the protein seem to be independently regulated [94].
The regulation of surfactant homeostasis carried out by SP-D is particularly important upon birth.
Newborn mice show a much larger pool size and an ultrastructure of SA and LA pools different to that
observed in adults. The postnatal change leading to a normalization of the pools has been suggested
to be initiated by the increased amount of PI of newly secreted surfactant (both in newborns and
adults) that promotes the association of SP-D to surfactant lipids, triggering the structural conversion
to small vesicles [93,94]. All these findings highlight how the particular composition and structure of
surfactant at the different levels of its functional cycle regulate alveolar homeostasis in detail, and how
the interactions between surfactant proteins and lipids are particularly essential for this task.
Maintaining lipid homeostasis inside the cell is crucial both for AE2C and AM, mainly through
the ATP-binding cassette transporters ABCA1 and ABCG1. These proteins are involved in the reverse
cholesterol transport by mediating efflux of excess cholesterol and phospholipids towards the plasma
(Figure 1). In AE2C, alteration of these proteins produces lipid accumulation and affects LB morphology,
secretion and recycling, suggesting an important role in surfactant homeostasis [35,170].
Alveolar macrophages are essential for surfactant lipids catabolism, accounting for around 20%
of its clearance [31]. Alterations affecting lipid degradation by AM entails accumulation of lipids in
Int. J. Mol. Sci. 2020, 21, 3708 11 of 39
these cells (the so-called foamy macrophages) that causes inflammation, and reduced clearance of
surfactant, leading to accumulation of impaired surfactant at the alveolar spaces. Factors involved
in these pathways, such as cluster of differentiation CD44, are thus regulators of lung homeostasis
and inflammation [171]. The main regulator of lipid catabolism in AM has been shown to be
granulocyte-macrophage colony stimulating factor (GM-CSF) (Figure 1). This factor does not affect
surfactant uptake by AM directly but promotes the maturation of these cells and activates proteins
involved in phospholipid and cholesterol clearance, as ABCA1 and ABCG1 [32,34,172]. On the other
hand, the administration of GM-CSF to mice with impaired AM development has been recently shown
to produce a decrease in the amount of SP-D, pointing to a cross-regulation of AE2C re-uptake and AM
catabolic pathways [33]. Surfactant would then mediate somehow the communication between both
cells, as it seems to occur also in relation to cholesterol metabolism, so that the increase of cholesterol
in surfactant has been described to trigger alteration of cholesterol metabolism in AM [34]. On the
other hand, an involvement of SP-B has been suggested in facilitating cholesterol efflux from AM to
surfactant, which would act as acceptor with the aim of reducing inflammation-induced cholesterol
accumulation in these cells [173]. A potential role of SP-B/cholesterol interactions in this activity has
still to be demonstrated. Regarding SP-C, its reported membrane fragmentation ability, together with
its tendency to partition into cholesterol-rich environments have been also suggested to be potentially
involved in regulatory mechanisms of surfactant homeostasis [69]. Intrinsic absence of SP-C in AM
with cholesterol accumulation in SP-C-KO mice leads to an impaired metabolism and the generation of
cholesterol crystals in AM cytoplasm, a phenotype that has been suggested to be the consequence of the
impairment of AE2C/AM cross-talk, and that could be mediated by the alveolar instability generated
by the absence of SP-C [78].
3.4. The Importance of Surfactant Anabolism/Catabolism Balance and Its Alteration
An altered lung surfactant homeostasis as a consequence of unbalanced anabolism/catabolism
leads to the generation of pulmonary alveolar proteinosis (PAP). PAP is a syndrome characterized by
the accumulation of alveolar surfactant and dysfunction of AM, thus producing respiratory deficiency
and alteration of the lung immune defense. The existence of such numerous proteins involved in
the regulation of lung lipid homeostasis entails a broad etiology for PAP, including alterations of
re-uptake/catabolism by AE2C or AM (as autoantibodies to GM-CSF, absence or alteration in GM-CSF
receptors colony stimulating factor 2 receptors alpha and beta, ABCA1, ABCG1, SP-D and GPR116) or
of surfactant secretion (GPR116). Besides this, mutations in genes required for the proper production
of surfactant (ABCA3, SP-B or SP-C) also leads to congenital PAP [16]. Regarding to the nature of the
accumulated lipids, the analysis of the lipidome of PAP samples from different etiologies revealed
similar results, including drastic increase of sphingolipids (mainly ceramide), free and sterified
cholesterol, PC and lysophosphatidylcholine [174].
Alteration of surfactant homeostasis can also occur upon exposure to external toxicity. Electronic
cigarettes have been found to alter lipid homeostasis in AE2C and AM, with effects in ABCA1, ABCA3,
LB structure and immune functions [175]. Finally, chronic alcohol consumption also disrupts lipid
homeostasis and immune responses in AM, increasing susceptibility to pulmonary infections [176].
In conclusion, the importance of a proper lipid homeostasis in the lung goes beyond the necessity
of maintaining sufficient but proportionate lipid levels to ensure surfactant function and alveolar
stability. Lipids play essential roles in lung physiology, and constitute a link between metabolism and
host defense, sensing and translating extracellular information to immune cells. As will be detailed
later, anionic phospholipids influence AM response to inflammatory stimuli and oxidized lipids and
cholesterol mediate and expand inflammatory responses [177]. Of note is the role of PLA2, involved in
surfactant lipid remodeling and degradation, in connecting surfactant turnover and oxidative stress
responses in AM [147].
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4. Anti-/Pro-Inflammatory Balance
The constant exposure of the lung to microorganisms from inhaled air at the upper respiratory tract
activates the immune response, which leads to transcriptional expression of inflammatory mediators
that coordinate the elimination of infected cells and pathogens. Resolution of inflammation and return
to homeostasis is induced by activation and secretion of endogenous anti-inflammatory factors [178].
However, aberrant activation of the inflammatory response leads to immunodeficiency, septic shock,
or induction of autoimmunity [179]. Therefore, the activation and resolution of inflammation must be
tightly regulated by immune mechanisms that decrease microbial burden by facilitating clearance of
inhaled pathogens, and control tissue damage caused by pathogens or by the host immune response
by modulating inflammatory responses [180]. Surfactant proteins and lipids have been shown to
provide immune protection against respiratory pathogens, both directly by limiting inflammation and
promoting pathogen clearance, and indirectly by activating molecular and cellular mechanisms that
contribute to restore lung homeostasis [15,181–183]. This part of the review summarizes the role of
surfactant proteins and lipids on the immune response against bacterial lipopolysaccharide (LPS), the
most potent pathogen-associated molecular pattern among bacterial cell wall components.
4.1. Interaction with Bacterial Lipopolysaccharide
Bacterial lipopolysaccharide, the major component of the outer membrane of Gram-negative
bacteria, strongly stimulates the innate or natural immunity in eukaryotic species [184]. LPS is composed
of a poly- or oligo-saccharide part linked to a membrane-anchoring lipophilic domain known as lipid A
or endotoxin (Figure 3). The polysaccharide part is commonly subdivided into the terminal O-specific
chain, whose composition varies within bacterial species, and the rather invariable core region, most
proximal to lipid A. Bacteria express either smooth LPS, which contains the O-antigen and complete
core oligosaccharides, or rough LPS, which lack O-antigen and possess progressively shorter core
oligosaccharides. Rough LPS is designated as Ra, Rb, Rc, Rd, and Re in order of decreasing core
length [185]. Strains with rough type LPS are more common among pathogens colonizing pulmonary
compartments [184,186,187].
Lipid A, which represents the conserved molecular pattern of LPS, consists of a β(1→6)-linked
diglucosamine backbone carrying two phosphate groups at positions 1 and 4’ of the glucosamine
residues and six or seven ester- and amide-linked saturated acyl chains of 12 and mostly 14 carbon
atoms in length [184] (Figure 3). Both phosphate groups and the myristoyl and lauroyl acyl chains
have been shown to be major determinants for specific recognition and activation of innate immunity.
LPS recognition by cell receptors requires a specific three-dimensional non-lamellar supramolecular
structure of LPS aggregates [185,188–190] (Figure 3).
Host responses to LPS are mainly mediated by the pattern recognition receptor Toll-like
receptor 4 (TLR4) [191]. The activation of TLR4 by LPS requires the interaction of LPS with several
receptor-proximal proteins (Figure 3). The lipopolysaccharide binding protein (LBP) binds to the
aggregated structures of LPS and transfers LPS monomers to the soluble or membrane-bound forms of
cluster of differentiation 14 (CD14) via specific recognition of the lipid A domain. CD14 subsequently
transfers LPS to the myeloid differentiation factor 2 (MD2), which forms a complex with TLR4.
LPS binding to MD2 induces a conformational change in TLR4 that promotes TLR4/MD2 dimerization
and the subsequent CD14-controlled internalization of TLR4 into endosomes [192], initiating the
signalling cascade [193]. Using different LPS analogs, Triantafilou and co-workers [194] showed that
the recruitment of these receptors is triggered by the 1-phosphoryl lipid A moiety of LPS.
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Figure 3. Host response to lipopolysaccharide (LPS). LPS is composed of lipid A, the hydrophobic
membrane-anchoring re ion, a d a hydrophilic part formed by the core oligosacc i n and the
O-antig n. The core olig saccharide region includes an outer core region, enriched in hexoses, and an
inner core region pr ximal to lipid A that contains 3-de xy-D-manno-octuloso ic acid [184]. The O-antigen,
also termed O-specific chain, contains up to 50 highly variable oligosaccharide units. Both the acyl chains
and the negative charges of the phosphate groups bound to the diglucosamine backbone of lipid A are
required for the recognition of LPS by cell receptors and the subsequent activation of the host immune
system. LPS molecules associate forming non-lamellar supramolecular structures that are recognized by
LBP, which transfers LPS monomers to CD14. LPS is subsequently transferred to the TLR4/MD2 complex,
triggering complex dimerization and initiating the signaling cascade. Interaction of surfactant protein
SP-A (functional form, octadecamer) with LPS modifies the aggregated LPS structure, inducing formation
of lamellar phases, and therefore preventing the recognition of LPS by LBP.
Surfactant proteins -A, -C and -D ha shown to act as LPS scavengers both in vitro and
in vivo [195–197], contributing to the cl e nd inactivation of LPS released by Gram-negative
bacteri . These proteins interact with differe t Ss [198–203]. While SP-D binds to the acyl chains
of lipid A [204] as well as to the heptoses and mannoses of the core [205,206] and O-antigen [207],
respectively, SP-A only binds to lipid A [208,209]. As a result, SP-A only binds to rough LPS since
the bulky headgroup of smooth LPS hinders the access of SP-A to the lipid A moiety. Although the
interaction of SP-A and SP-D with LPS was firstly described as being mediated by calcium [208–210],
it has been shown that both collectins bind to Re-LPS in the absence of this cation [202,203,211]. On the
other hand, SP-C binds to the lipid A moiety of LPS by its N-terminal segment, probably through
electrostatic interactions between the polar and basic resi ues of the protein and th negatively charged
terminal 1-phosphate group at th reducing end of the lipid A disaccharide [199]. Similarly, SP-A
binding to the 1-phosphate of lipid A [212] may involve electrostatic interactions with a cluster of
basic residues located in the CRD of the protein [203,213]. Since the negative charges of the phosphate
groups are required for LPS binding to LBP [214] and the activation of the TLR4/MD2 complex [215],
the interaction of SP-C and SP-A with 1-phosphate may shield this functional group, blocking some of
the physiological responses to LPS in the lungs. This hypothesis is supported by the finding that SP-A
prevents the interaction of Re-LPS with LBP [216]. SP-A also agglomerates rough LPS aggregates in
the presence of calcium [203] and rearranges the aggregated structure of LPS, which changes from
inverted to lamellar phases [212] (Figure 3). Both the clustering of LPS aggregates and their lamellar
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structure would reduce LPS toxicity by preventing the recognition of LPS by LBP, and the subsequent
initiation of the LBP/CD14 pathway towards inflammatory reactions.
Surfactant lipids can facilitate the scavenger action of surfactant proteins. In this regard, it has
been shown that LPS incorporates in vesicles of a modified porcine pulmonary surfactant [217]
and films of surfactant lipids [196,211]. Repulsive interactions between smooth LPS and surfactant
lipids facilitate the interaction of SP-A with the lipid A moiety of smooth LPS, which results in the
extraction of LPS molecules [196]. Additionally, incorporation of LPS into surfactant membranes would
decrease the endotoxicity of LPS by abrogating the interaction of lipid A with its cellular receptors.
This hypothesis is supported by earlier studies reporting that the biological activity of LPS is reduced
when LPS is incorporated into liposomes [218]. Alternatively, surfactant lipids may incorporate into
LPS aggregates, changing the aggregated structure of LPS, and hence, reducing its ability to stimulate
immune cells [190].
4.2. Interaction with Pattern-Recognition Receptors
In addition to the direct interaction with LPS, surfactant proteins also modulate the cellular
inflammatory response via interaction with pattern-recognition receptors and associated molecules.
For instance, SP-A modulates the cellular response to smooth LPS, although this LPS is not a ligand for
SP-A, by binding to CD14 [210] and the TLR4/MD2 complex [219]. Thus, the interaction between SP-A
and LPS receptors significantly decreases the binding of smooth LPS and consequently prevents the
smooth LPS-elicited cellular response [210,219]. In contrast, SP-A significantly enhances the binding of
rough LPS to CD14 [210] and does not attenuate rough LPS binding to TLR4/MD2 [219]. This effect
has been related to the formation of a SP-A/CD14/rough LPS complex in which the amphipathic neck
domain of SP-A would bind to the leucine-rich region of CD14, whereas the CRD would bind to the
lipid A moiety of rough LPS, allowing the transfer of LPS molecules to the TLR4/MD2 complex and
initiating physiological responses against pathogens [208]. Formation of a ternary complex with CD14
and LPS has also been proposed for SP-C, which, like SP-A, binds to CD14 increasing the binding of
rough LPS [220]. SP-C-containing phospholipid vesicles, but not lipid vesicles alone, block LPS-induced
cytokine production by a TLR4-dependent mechanism in human embryonic kidney HEK293T cells [197].
Whether this effect is due to the direct interaction of SP-C with TLR4 and/or MD2 needs to be clarified.
On the other hand, SP-D binds to CD14 and TLR4/MD2 through its CRD [208,221,222], decreasing the
binding of both smooth and rough LPS to CD14 [208] and TLR4/MD2 [223]. This suggests that SP-D
may act as a negative regulator to protect against a chronic inflammatory state induced by the release
of numerous inflammatory mediators as a consequence of the interaction of SP-A and SP-C with rough
LPS and its receptors.
On the other hand, anionic surfactant lipids PG and PI inhibit LPS-induced cell activation
by competitive binding to LPS receptors [224,225]. While PI interferes with the interactions
between LPS and CD14 [225–227], PG inhibits LPS binding to LBP, CD14 and MD2 [190,224,225,228].
Alternatively, surfactant lipids can prevent activation of TLR4 by LPS by incorporating it into the plasma
membrane. Thus, DPPC has been shown to inhibit the translocation of TLR4 to raft domains [229],
precluding the co-localization of CD14 and TLR4 in lipid rafts that is required for LPS-induced activation
of TLR4 [230]. Voelker and co-workers [231] have suggested that inhibition of Toll-like receptor function
by surfactant lipids would set a threshold for the engagement of inflammatory cascades in the lung,
preventing inflammation by casual environmental stimuli like environmental levels of particulated
LPS while allowing a robust inflammatory response during established bacterial infections.
5. Antimicrobial Effect
Surfactant proteins and lipids also contribute to lung homeostasis by exerting antimicrobial effects
(Figure 4). Animal models of SP-C and collectin deficiencies show a significant defect in host defence
since: (i) SP-C, SP-A, and SP-D knock-out mice are more susceptible to bacterial, fungal, and viral
infections [157,232–235], (ii) SP-A−/− and SP-D−/− mice show reduced uptake of these microbes by
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alveolar macrophages (reviewed in [236]), and (iii) bacterial clearance is restored by intratracheal
administration of SP-A [237].
Lung collectins SP-A and SP-D prevent microbial dissemination by direct binding to a broad
range of microorganisms, including viruses, fungi and Gram-positive and Gram-negative bacteria
(reviewed in [236,238,239]). These proteins recognize different pathogen-associated molecular patterns
on the surface of microorganisms: LPS in Gram-negative bacteria, lipoteichoic acid and peptidoglycan in
Gram-positive bacteria, lipoarabinomanan in mycobacteria, phospholipids in mycoplasma, glucan and
mannose in fungi, and glycoproteins in fungi and viruses [236,240–244]. The association of SP-A and
-D with pathogens may result in microbial aggregation, which facilitates mucociliary clearance by the
respiratory tract, prevents attachment of pathogens to cell surfaces, inhibits microbial colonization and
invasion, and may favor microbial phagocytosis [245]. SP-A and SP-D also act as opsonins, increasing
the association, uptake and killing of the microorganisms [246]. This requires specific interactions with
different receptors on phagocytic cells, such as surfactant protein receptor 210 (SP-R210) [247], a specific
receptor for SP-A [248], the putative opsonin receptor glycoprotein 340 (gp340), a macrophage scavenger
receptor family member, to which both SP-A and SP-D bind [249,250], or the immunoglobulin G [251].
Interaction of the globular heads of lung collectins with pathogen-associated molecular patterns promotes
the presentation of the collagenous tails to calreticulin/cluster of differentiation 91 (CD91) on the surface
of phagocytic cells, stimulating phagocytosis and pro-inflammatory responses [252]. Lung collectins can
also stimulate phagocytosis through upregulation of the expression of cell-surface receptors involved in
microbial recognition in phagocytic cells [253], such as the mannose receptor [254,255] or the class A
scavenger receptor [256]. The precise receptor(s) involved in the activation of the signal transduction
pathways that lead to an increased trafficking of pathogen recognition receptors to the plasma membrane
remains elusive. Alternatively, lung collectins may promote microbial clearance by regulating the
complement system. Thus, SP-D enhances the activity of complement component 1q (C1q) by forming
additional binding sites for C4b and C3b [257], two complement binding protein complexes involved in
opsonization [258]. On the contrary, association of SP-A with C1q may down-regulate complement
activity, preventing C1q-mediated complement activation and inflammation [259]. Lung collectins are
also involved in pathogen clearance by neutrophil extracellular traps (NETs), DNA-based extracellular
traps that capture and kill microbes. Simultaneous binding of SP-D to bacteria and NETs promotes
bacterial trapping by the NETs [260]. On the other hand, since LPS efficiently induces the formation
of NETs [261], binding of SP-D to LPS has been recently shown to attenuate NETs formation [262].
This suggests that SP-D may regulate the balance between the antimicrobial activity of NETs and the
exacerbated immune response and tissue injury as well as surfactant inhibition induced by an excessive
presence of NETs in the lung.
SP-A and SP-D directly affect the growth and viability of microorganisms [263]. Lung collectins
have been found to inhibit the growth of different bacteria like Escherichia coli, Klebsiella pneumoniae,
Enterobacter aerogenes, Legionella pneumophila,Mycobacterium avium, andMycoplasma pneumoniae [236,240].
This bacteriostatic effect has been related to the ability of SP-A and SP-D to increase the permeability
of the microbial cell membrane [264]. Gram-negative bacterial strains decorated with rough LPS
are permeabilized more effectively by SP-A and SP-D than strains containing smooth LPS [264].
Although the mechanism of bacterial permeabilization by lung collectins is unclear, it seems to require a
direct interaction between SP-A and LPS. In this regard, Kuzmenko and co-workers [265] suggested that
SP-A distorts or perturbs membrane structure, creating defects that allow small hydrophilic molecules
to enter and translocate through the bilayer. Such defects seem to be related to the formation by SP-A of
extensive lattice-like structures on the surface of LPS-containing layers [211,266]. Pulmonary collectins
also decrease the viability of Histoplasma capsulatum by increasing the permeability of the fungal cell
wall in a calcium-dependent manner [267]. Although the precise mechanism involved in membrane
permeabilization of this fungi is unknown, McCormack and co-workers [267] have suggested that
membrane disruption could be due to the formation of calcium bridges between the collectins and
fungal phospholipids. Growth of microorganism is also affected by the agglutinating activity of lung
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collectins, i.e., SP-D agglutinates Candida albicans [195,238] decreasing the availability of substrate to
agglutinated yeasts [195].Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 16 of 40 
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aggregation/agglutination; (ii) enhancing microbial phagocytosis via opsonization, upregulation of 
the expression of cell-surface receptors involved in microbial recognition by phagocytic cells, and 
regulation of the complement system; and (iii) favoring bacterial trapping by NETs through 
simultaneous binding to bacteria and NETs. In addition, SP-A (18-mer), SP-C and SP-D (here only 12-
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infectivity, preventing the adhesion and internalization of bacteria and viruses by alveolar epithelial 
cells. 
SP-A and SP-D directly affect the growth and viability of microorganisms [263]. Lung collectins 
have been found to inhibit the growth of different bacteria like Escherichia coli, Klebsiella pneumoniae, 
Enterobacter aerogenes, Legionella pneumophila, Mycobacterium avium, and Mycoplasma pneumoniae 
[236,240]. This bacteriostatic effect has been related to the ability of SP-A and SP-D to increase the 
permeability of the microbial cell membrane [264]. Gram-negative bacterial strains decorated with 
rough LPS are permeabilized more effectively by SP-A and SP-D than strains containing smooth LPS 
Figure 4. Antimicrobial activity of surfactant lipids and proteins. Lung collectins contribute to microbial
clearance by: (i) facilitating mucociliary clearance through microbial aggregation/agglutination;
(ii) enhancing microbial phagocytosis via opsonization, upregulation of the expression of cell-surface
receptors involved in microbial recognition by phagocytic cells, and regulation of the complement
system; and (iii) favoring bacterial trapping by NETs through simultaneous binding to bacteria and NETs.
In addition, SP-A (18-mer), SP-C and SP-D (here only 12-mers are represented) directly affect growth and
viability of microorganisms by increasing the permeability of the microbial cell membrane. Surfactant
lipids and proteins also inhibit microbial infectivity, preventing the adhesion and internalization of
bacteria and viruses by alveolar epithelial cells.
On the other hand, a surfactant lipid mixture composed of DPPC, palmitoyloleoylphosphatidylcholine
and palmitic acid has been shown to interfere with the interaction of non typableHaemophilus influenzaewith
pneumocytes by binding to the bacteria and preventing bacterial adhesion and internalization in alveolar
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epithelial cells [268]. In addition, these lipids can be endocytosed by pneumocytes by binding to the
scavenger receptor class B type I, blocking bacterial uptake [268]. In vivo studies show that administration
of the hydrophobic fraction of native surfactant, containing surfactant lipids and proteins SP-B and SP-C,
significantly diminishes bacterial load in bronchoalveolar lavage and lung tissue of mice infected with this
pathogen [268]. Although this antimicrobial activity has been ascribed to surfactant lipids, it is plausible
that surfactant proteins SP-C and SP-B may play a bactericidal role against other pathogens. In this regard,
bovine lung surfactant extract, a mixture of DPPC, palmitoyloleoylphosphatidylglycerol (POPG) and
SP-B/-C, and a synthetic model lung surfactant, but not the lipids alone, all show antimicrobial activity
against E. coli and Staphylococcus aureus [269]. SP-B and SP-C have a strong affinity for iron-regulated
surface determinant proteins A and C [269], cell-wall receptors of S. aureus involved in the process of
heme-iron acquisition. Binding to these receptors would disturb the bacterial surface, enhancing bacterial
killing [269]. SP-B and SP-C also bind to β-barrel assembly machinery protein A and lipopolysaccharide
transport protein D, twoβ-barrell proteins at the outer membrane of E. coli, lethally disrupting the bacterial
outer membrane [269]. Additionally, incubation of E. coli with SP-C incorporated into liposomes of
DPPC and POPG, but not the lipids alone, decreases bacterial growth by altering the membrane [269].
Although the mechanism by which SP-C disturbs the outer membrane is not clear, SP-C binding to LPS
could be a key feature to disrupt the outer membrane and induce the release of LPS, rendering the cells
permeable. This would facilitate the access of SP-C to the plasma membrane, where this protein would
exert an antimicrobial activity [269]. The antimicrobial action of SP-B, which has been shown to aggregate
and kill clinical isolates of K. pneumoniae, P aeruginosa, S. aureus and group B streptococcus by increasing
membrane permeability [270], is inhibited by surfactant lipids, mainly POPG [270]. This suggests that
endogenous SP-B may not play by itself a significant role in alveolar host defense. However, proSP-B,
the SP-B precursor may be proteolitically cleaved into smaller peptide fragments that could retain its
antimicrobial activity in the presence of surfactant lipids. In this regard, SP-BN, the N-terminal propeptide
of SP-B (residues 31-191), which encodes a saposin-like domain, promotes the uptake of bacteria by
macrophages and exerts a bactericidal effect at acidic pH, consistent with a lysosomal, antimicrobial
function [271].
Binding of surfactant lipids and proteins to viruses results in enhanced phagocytosis and viral
neutralization at the initial stages of infection [243,272]. Regarding lung collectins, the viral neutralizing
activity of SP-D is enhanced compared to SP-A, playing an important role in the innate immune
response to different viruses such as vaccinia or influenza A virus. The antiviral activity of lung
collectins is related to their ability to bind to different proteins on the viral surface [243]. In general,
interactions of lung collectins with viral proteins are calcium-dependent, involve the CRD and are
facilitated by the multimerization of the full-length protein. The collagen domain of SP-A may
also play a role in the antiviral action of the protein, since a recombinant variant of human SP-A
composed of the neck and carbohydrate recognition domains can promote the replication of influenza
A virus [273]. While SP-A prevents the recognition of influenza A virus by host cell receptors through
binding of the sialylated asparagine 187 residue of SP-A to hemagglutinin [274,275], binding of SP-D
to mannose-rich oligosaccharides close to the sialic acid-binding sites of hemagglutinin reduces viral
uptake into epithelial cells [276,277], and sterically blocks the access of neuraminidase to surface-bound
substrates [278,279] thereby preventing viral dissemination. This inhibitory effect has been related
to the bulky collagen domain in the extended structure of dodecameric SP-D [279]. SP-A and SP-D
also bind to the human immunodeficiency virus envelope glycoprotein 120 [280–282] and to the
fusion and attachment glycoproteins of respiratory syncytial virus, F and G, respectively [283–286],
neutralizing viral infectivity and inhibiting viral replication [281]. SP-A can mediate phagocytosis
of herpes simplex virus type 1 by alveolar macrophages via its N-linked oligosaccharides [287].
To which viral surface protein(s) SP-A binds is not known. However, since SP-A binding to herpes
simplex virus is inhibited by heparin, and heparin is known to bind to viral glycoproteins B and C,
these proteins are likely candidates [287]. Other viral surface proteins recognized by lung collectins are
the spike glycoprotein of the severe acute respiratory syndrome (SARS) coronavirus [288], the outer
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capsid glycoprotein 7 of non-enveloped rotavirus [289], and the A27 protein of vaccinia virus [290].
The potential interaction of surfactant proteins with proteins at the surface of the SARS-CoV-2 virus
responsible of the emergent CoVid19 pandemic is currently under intensive scrutiny. Interactions of
lung collectins with viral proteins can also result in deleterious effects during viral infections. In this
regard, binding of SP-D to the glycoprotein of Ebola virus enhances infection in mammalian cells,
facilitating the attachment of SP-D-bound virus to host cell co-receptors and probably affecting the
inflammatory response [291]. On the other hand, the finding that constitutive expression of misfolded
SP-C increases susceptibility to viral-induced cell death [292] suggests an antiviral activity for SP-C.
This hypothesis is supported by the increased susceptibility of SP-C deficient mice to respiratory
virus infection [235], which is reduced upon transgenic restoration of SP-C [197]. Surfactant lipids
also play antiviral roles. Different molecular species of PG and PI have been shown to bind to
respiratory syncytial virus and influenza A virus, inhibiting their interaction with the epithelial cell
surface [231,293–296]. Neither the structural basis for lipid antagonism nor the inhibition mechanisms
are known. It has been proposed that POPG and PI could act as decoy ligands for Toll-like receptors,
given the structural similarities between the lipid A moiety of LPS and the anionic surfactant lipids [183].
Likewise, the structural similarities between anionic surfactant lipids and sialic acid containing lipid
receptors for the hemagglutinin of H1N1 influenza A virus suggest that these lipids could also act as
decoy receptors for viral attachment proteins [183].
The antimicrobial function of surfactant components may be modulated by interaction with
other antimicrobial components of the alveolar fluid. Cooperative interactions of SP-A and SP-D
with antimicrobial peptides have been suggested. For example, binding of SP-A to SP-BN results
in synergistic activity against SP-A– and SP-BN–resistant capsulated K. pneumoniae both in vitro
and in vivo [253]. On the other hand, binding of SP-D to human neutrophil defensins results in
antagonistic or cooperative effects on the hemagglutinin inhibitory and neutralizing activity of
SP-D [297]. These effects depend on the viral strain and the multimeric forms of both proteins,
with higher weight multimers precipitating SP-D in bronchoalveolar lavage fluid and thereby, reducing
its hemagglutinin inhibitory activity [297]. On the contrary, combinations of SP-D with human
β-defensins 5 and 6 show additive activity against influenza A virus [298]. SP-A, SP-D and the scavenger
receptor-rich gp340 act cooperatively against influenza A virus, inducing viral aggregation and
inhibiting hemagglutination [299]. Although both collectins bind to gp340 [249,250], this cooperative
effect does not appear to require a direct interaction with gp340, at least for SP-D [299]. Whether this is
also true for SP-A, needs to be clarified. Additionally, lung collectins can modulate the activity and
toxicity of some antimicrobial peptides. By binding to β-defensin 3, SP-A negatively regulates the
cytotoxicity of this peptide on epithelial cells without affecting its antimicrobial activity, protecting
the lung epithelium from injury caused by an excess amount of β-defensin 3 liberated during
inflammation [300].
6. Alveolar Epithelial Homeostasis
Surfactant proteins also contribute to the homeostasis of the alveolar epithelium by modulating
apoptosis, promoting clearance of apoptotic cells, and enhancing tissue repair [15].
6.1. Modulation of Apoptosis
Alveolar epithelial apoptosis is an important contributor to the pathophysiology of lung diseases
since severe alveolar epithelial apoptosis increases alveolar capillary permeability, and causes leakage
of serum into alveoli and loss of compartmentalization with unrestricted mechanical transduction and
signaling from the airways [301]. Excessive apoptosis may therefore affect the outcome of lung diseases,
including adult respiratory distress syndrome [302], chronic obstructive pulmonary disease [303],
and pulmonary fibrosis [304]. Therefore, a well-balanced interplay of cell apoptosis and proliferation
is required to maintain the integrity and function of the lung.
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Lung collectins have been shown to play a key role regulating apoptosis of alveolar epithelial
cells apoptosis. In this regard, SP-D has been shown to decrease apoptosis both in vitro and in vivo.
A recent study shows that SP-D-deficient mice have higher level of apoptotic cells in their alveolar
spaces than wild type mice and intratracheal administration of recombinant SP-D reduces levels of
apoptotic cells [263]. This reduction in apoptosis is due to a delayed activation of caspase 8 and 3
and externalization of phosphatidylserine [305], the aminophospholipid that in normal conditions
is located in the inner leaflet of the plasma membrane, but flips to the outer leaflet in dying cells.
Janssen et al. [306] have proposed that SP-A and SP-D suppress the phagocytic function of alveolar
macrophages through tonic interaction with the transmembrane receptor signal inhibitory regulatory
protein alfa (SIRPα) in the resting, noninflamed lung. Binding of SP-A or SP-D to SIRPα may facilitate
the interaction of this receptor with cluster of differentiation CD47, and the subsequent negative control
of phagocytosis by innate immune cells [307]. In type II cells, binding of SP-A to its receptor initiates
a signaling pathway that regulates apoptosis through tyrosine phosphorylation and activation of
phosphatidylinositol 3-kinase [308]. On the other hand, it has been recently demonstrated that the
interaction of interleukin 8, a chemokine produced by macrophages and epithelial cells, with SP-A
exacerbates cell damage in acute lung injury through inhibition of SP-A, promoting cell viability and
suppressing apoptosis [309]. Interleukin 8 also binds to SP-B [309], inhibiting the protective effect of
this protein on calcium ion transport. This would result in an increase of intracellular calcium ions that
may induce passive depolymerization of cytoskeleton and destroy the endothelial barrier [310].
Regarding surfactant lipids, little is known about their role in apoptosis. Supplementation
of Poractant alfa (Curosurf), an exogenous porcine-derived surfactant composed of surfactant
lipids, SP-B, and SP-C, with POPG or dioleoylphosphatidylglycerol reduces alveolar epithelial
cell apoptosis [311,312]. How these phospholipids regulate apoptosis is unknown, but they are
supposed to act directly on alveolar epithelial cells [311]. Surfactant proteins SP-B and SP-C are not
involved in principle in regulation of apoptosis. However, it has been shown that mutations in the
SP-C gene produce aberrant forms of SP-C that can generate accumulation of aggregated forms of
proSP-C, causing misfolded protein stress responses, inhibiting proteasome function, and activating
caspase-3-mediated apoptosis [313].
6.2. Efferocytosis
Non-inflammatory removal of dying cells is important for maintenance of lung tissue homeostasis
since apoptotic cells can undergo necrosis, releasing potentially damaging pro-inflammatory molecules
and antigens that cause autoimmunity [314] and the eventual destruction of alveolar walls [315].
Lung collectins enhance the ingestion of apoptotic cells by alveolar macrophages [316,317], being SP-D
a more potent promoter of apoptotic cell clearance than SP-A [316]. Removal of apoptotic cells by
SP-A and SP-D occurs through simultaneous interaction with apoptotic cells and surface receptors
on alveolar macrophages. The interaction of SP-A and SP-D with dying cells involves recognition of
intracellular molecules that become exposed on the outside of the cell upon apoptosis. In this regard,
both collectins have been shown to bind to DNA [318,319] and myeloperoxidase [320], a specific
intracellular defence molecule of neutrophils that has been proposed to act as a bridging molecule
between phosphatidylserine epitopes on apoptotic cells and SP-A, facilitating the internalization of
dying cells by macrophages. On the other hand, the macrophage receptors calreticulin/CD91 and myosin
18A are involved in collectin-mediated clearance of dead cells [15,321]. Interestingly, the interactions
of SP-A and SP-D with these receptors, as well as the binding of SP-D to DNA, occur through their
collagenous domains [15,319,322,323]. Therefore, the potency of SP-D as promoter of apoptotic cell
clearance may be linked to its large and extended collagen steams, which would facilitate the interaction
between the macrophage receptors and apoptotic cells. This would allow the binding of calreticulin to
dying cells and their subsequent targeting for removal by phagocytosis [324].
In vivo administration of Poractant alfa increases the clearance of apoptotic neutrophils [325].
Whether this effect is due to surfactant lipids or to surfactant proteins SP–B and/or –C is not clear.
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Although the mechanisms involved in this effect remain elusive, Willems and co-workers [325] have
proposed that surfactant lipids could compete with SIRPα for binding SP-A and SP-D, thereby preventing
their suppressive effects on phagocyte function.
6.3. Tissue Repair
Pathogens, damaged cells or toxic compounds may trigger an exacerbated or chronic inflammatory
response that damages lung tissue, playing a critical role in the pathology and progression of different
lung diseases such as emphysema [326] and lung fibrosis [327]. Resolution of inflammation and
the subsequent regeneration of lung tissue requires replacement of injured cells by cells of the
same type and the subsequent fibroplasia or fibrotic scarring in which connective tissue replaces
normal parenchymal tissue, associated with an alternative, anti-inflammatory M2 polarization of
macrophages [328–330]. Willems and co-workers demonstrated that pulmonary surfactant plays
a role in the regeneration and remodeling of lung parenchyma [325]. SP-A has been shown to
participate in the processes that control lung epithelial cell proliferation and apoptosis by binding
to transforming growth factor β (TGF-β) [325,331], a potent inhibitor of epithelial cell proliferation.
Formation of the SP-A/TGF-β complex protects TGF-β from inactivation by the latency-associated
peptide [331] and facilitates TGF-β binding to its receptors, inducing signaling cascades involved
in cell cycle progression and proliferation [127]. SP-A and SP-D also contribute to tissue repair by
activating the polarization of alveolar macrophages to a M2 phenotype [323,332]. This effect has been
related to the binding of the collagen domain of SP-A to myosin 18 [323]. This receptor, also known
as SP-R210, forms a pro-inflammatory complex with CD14 and class A scavenger receptor (SR-A)
that promotes internalization of LPS and subsequent signaling [333]. Therefore, SP-A may inhibit
the SP-R210/CD14/SR-A complex, contributing to regulation and resolution of the inflammatory
response [333]. In addition, through binding to interferon gamma (IFN-γ), SP-A suppresses IFN-γ
interaction with its receptor, inhibiting the polarization of alveolar macrophages to a pro-inflammatory
M1 phenotype [334] that has been shown to hinder fibroplasias [328].
On the other hand, SP-C [78] also plays a key role in maintaining alveolar integrity and repair since
SP-C-null patients and animal models of SP-C deficiency develop fibrosis [105,335]. Moreover, mutations
or decreased expression of the gene encoding SP-C, causes alveolar type II cell injury and aberrant repair
of lung tissue to develop pulmonary fibrosis [335–337]. In this regard, Glasser and co-workers [234]
showed that SP-C-deficient mice express markers of macrophage alternative activation associated with
advancing pulmonary fibrosis. This suggests that SP-C negatively regulates the alternative activation of
macrophages, preventing the development of fibrosis. Although the role of SP-C deficiency in fibrosis
development has been documented by numerous lines of evidence, little is known about the interactions
of SP-C with macrophage receptors involved in regulation of macrophage polarization.
7. Conclusions: Surfactant as a Hub in Alveolar Homeostasis
The extensive network of lipid–protein and protein–protein interactions described by this review
to occur between lung surfactant molecules and host and pathogen cells at the alveolar spaces put
surfactant structures at the center of lung homeostasis. Through these interactions, the surfactant
network likely integrates signals from epithelial cells and the cells responsible for the innate and induced
immune response, leading to a coordinated modulation of the respiratory scenario. This includes a
proper control over an environment that needs to be at the same time protective against mechanical
and biophysical demands and against infection, but relatively tolerant with the occasional entrance of
exogenous particles and microorganisms inhaled within the thousands of liters of air breathed every day.
On the other hand, lung surfactant-associated interactions and processes have to coordinate appropriate
responses to challenges triggered by different physiopathological contexts, whose resolution defines
the edge between health and illness. A full understanding of the different levels of complexity of the
surfactant network will open unprecedented diagnostic and therapeutic opportunities.
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ABCA1 ATP binding cassette subfamily A member 1
ABCA3 ATP binding cassette subfamily A member 3
ABCG3 ATP binding cassette subfamily G member 3
AE1C alveolar epithelial type I cells
AE2C alveolar epithelial type II cells
AM alveolar macrophages
ARDS acute respiratory distress syndrome
C1q complement component 1q
CCT cytidine triphosphate-phosphocoline cytidyltransferase
CD14 cluster of differentiation 14
CD91 cluster of differentiation 91
CRD carbohydrate recognition domain
DPPC dipalmitoylphosphatidylcholine
EMC3 endoplasmic reticulum membrane protein complex subunit 3
ER endoplasmic reticulum
GM-CSF granulocyte-macrophage colony stimulating factor
gp340 glycoprotein 340
GPR116 G-protein coupled receptor 116
IFN-γ interferon gamma
LA large aggregates
LB lamellar bodies
LBP lipopolysaccharide binding protein
LPCAT1 acyl CoA:lysophosphatidylcholine acyltransferase
LPS lipopolysaccharide
MD2 myeloid differentiation factor 2
NETs neutrophil extracellular traps
P63 tumor protein 63
PAP pulmonary alveolar proteinosis
PC phosphatidylcholine
PG phosphatidylglycerol
PI phosphatidylinositol
PLA2 phospholipase A2
POPG palmitoyloleoylphosphatidylglycerol
RCT reverse cholesterol transport
RDS respiratory disease syndrome
SA small aggregates
SARS severe acute respiratory syndrome
SIRPα signal inhibitory regulatory protein alfa
SNARE N-ethylmaleimide-sensitive factor attachment receptor
SP-A surfactant protein A
SP-B surfactant protein B
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SP-BN N-terminal propeptide of SP-B
SP-C surfactant protein C
SP-D surfactant protein D
SP-R210 surfactant protein receptor 210
SR-A class A scavenger receptor
STAR10 steroidogenic acute regulatory-related lipid transfer protein 10
TGF-β transforming growth factor β
TLR4 Toll-like receptor 4
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